Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus.

[1]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Masahiko Hoshijima,et al.  Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery , 2002, Nature Medicine.

[3]  R. Aikawa,et al.  Cardiomyocyte-specific Gene Expression Following Recombinant Adeno-associated Viral Vector Transduction* , 2002, The Journal of Biological Chemistry.

[4]  J. Oyama,et al.  Gene Therapy Strategy for Long-Term Myocardial Protection Using Adeno-Associated Virus-Mediated Delivery of Heme Oxygenase Gene , 2002, Circulation.

[5]  Hiroshi Sato,et al.  Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: Amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Biegel,et al.  Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Y. Kan,et al.  Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Samulski,et al.  Adeno-associated virus vectors for gene therapy: more pros than cons? , 2000, Molecular medicine today.

[9]  J. Isner,et al.  Left Ventricular Electromechanical Mapping to Assess Efficacy of phVEGF165 Gene Transfer for Therapeutic Angiogenesis in Chronic Myocardial Ischemia , 2000, Circulation.

[10]  Kotoku Kurachi,et al.  Kinetics of Recombinant Adeno-Associated Virus-Mediated Gene Transfer , 2000, Journal of Virology.

[11]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[12]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[13]  M. Post,et al.  Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. , 1999, Circulation.

[14]  M. Kay,et al.  Adeno-associated virus vectors and hematology. , 1999, Blood.

[15]  E. Svensson,et al.  Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. , 1999, Circulation.

[16]  J. Isner,et al.  Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. , 1998, Circulation.

[17]  R. Samulski,et al.  Selective and rapid uptake of adeno-associated virus type 2 in brain. , 1998, Human gene therapy.

[18]  D. Russell,et al.  Adeno-associated virus vector integration junctions , 1997, Journal of virology.

[19]  U. Ikeda,et al.  Gene transfer into vascular cells using adeno-associated virus (AAV) vectors. , 1997, Cardiovascular research.

[20]  James M. Wilson,et al.  Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.

[21]  S. Ponnazhagan,et al.  Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. , 1997, Human gene therapy.

[22]  R. Strumpf,et al.  Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. , 1996, The Annals of thoracic surgery.